NASDAQ
SPRC

Scisparc Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Scisparc Ltd Stock Price

Vitals

Today's Low:
$0.1512
Today's High:
$0.1748
Open Price:
$0.161
52W Low:
$0.141
52W High:
$1.59
Prev. Close:
$0.149
Volume:
3135029

Company Statistics

Market Cap.:
$2.08 million
Book Value:
0.949
Revenue TTM:
$1.35 million
Operating Margin TTM:
-615.22%
Gross Profit TTM:
$1.03 million
Profit Margin:
-192.43%
Return on Assets TTM:
-50.48%
Return on Equity TTM:
-35.53%

Company Profile

Scisparc Ltd had its IPO on 2021-08-30 under the ticker symbol SPRC.

The company operates in the Healthcare sector and Biotechnology industry. Scisparc Ltd has a staff strength of 3 employees.

Stock update

Shares of Scisparc Ltd opened at $0.16 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.15 - $0.17, and closed at $0.16.

This is a +6.38% increase from the previous day's closing price.

A total volume of 3,135,029 shares were traded at the close of the day’s session.

In the last one week, shares of Scisparc Ltd have increased by +2.26%.

Scisparc Ltd's Key Ratios

Scisparc Ltd has a market cap of $2.08 million, indicating a price to book ratio of 0.4159 and a price to sales ratio of 0.

In the last 12-months Scisparc Ltd’s revenue was $1.35 million with a gross profit of $1.03 million and an EBITDA of $-8100000. The EBITDA ratio measures Scisparc Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Scisparc Ltd’s operating margin was -615.22% while its return on assets stood at -50.48% with a return of equity of -35.53%.

In Q1, Scisparc Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Scisparc Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scisparc Ltd’s profitability.

Scisparc Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5197. Its price to sales ratio in the trailing 12-months stood at 0.

Scisparc Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.61 million
Total Liabilities
$4.16 million
Operating Cash Flow
$0
Capital Expenditure
$27000
Dividend Payout Ratio
0%

Scisparc Ltd ended 2024 with $10.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.61 million while shareholder equity stood at $6.45 million.

Scisparc Ltd ended 2024 with $0 in deferred long-term liabilities, $4.16 million in other current liabilities, 58592000.00 in common stock, $-63569000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.57 million and cash and short-term investments were $3.57 million. The company’s total short-term debt was $27,000 while long-term debt stood at $0.

Scisparc Ltd’s total current assets stands at $4.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $168000.00 compared to accounts payable of $1.20 million and inventory worth $668000.00.

In 2024, Scisparc Ltd's operating cash flow was $0 while its capital expenditure stood at $27000.

Comparatively, Scisparc Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.16
52-Week High
$1.59
52-Week Low
$0.141
Analyst Target Price
$

Scisparc Ltd stock is currently trading at $0.16 per share. It touched a 52-week high of $1.59 and a 52-week low of $1.59. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.35 and 200-day moving average was $0.63 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.

Around 161% of the company’s stock are held by insiders while 346.3% are held by institutions.

Frequently Asked Questions About Scisparc Ltd

The stock symbol (also called stock or share ticker) of Scisparc Ltd is SPRC

The IPO of Scisparc Ltd took place on 2021-08-30

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$50.59
-0.05
-0.1%
$6.43
0.21
+3.38%
$681.6
-29.35
-4.13%
$0.02
0
+8.11%
$1.3
0.09
+7.39%
$16.5
-0.1
-0.6%
$10.62
0
0%
$21.1
0
0%
Akebia Ther (AKBA)
$1.26
-0.04
-3.08%
$123.5
-4.55
-3.55%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and epilepsy and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation, as well as a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Address

Tower A, Tel Aviv, Israel, 6971916